NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,233.75 +32.48 (+0.19%) CRUDE OIL
82.96 +0.15 (+0.18%) GOLD FUTURES
2,331.40 -7.00 (-0.30%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,504.21 -1,832.42 (-3.44%)
Capricor Therapeutics, Inc. (CAPR)
After hours:
| Previous close | 4.82 |
| Open | 5.26 |
| Bid | 5.01 x 300 |
| Ask | 5.05 x 200 |
| Day's range | 5.00 - 5.65 |
| 52-week range | 2.68 - 8.22 |
| Volume | |
| Avg. volume | 306,345 |
| Market cap | 158.775M |
| Beta (5Y monthly) | 4.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
- GlobeNewswire
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences. Event:H.C. Wainwright 2nd Annual Cell Therapy ConferencePresentation:March 26, 2024 at 2:00 p.m. ETFormat:Virtual fireside chat and one-on-one meetings Event:Cantor Fitzgerald’s Muscul
- GlobeNewswire
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-10
